R&D Systems uses cookies to provide you with a great website experience. By continuing to use this website you acknowledge this and agree to our cookie policy. Learn More
Detects human TWEAK in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant human (rh) BAFF, rhFas Ligand, rhGITR Ligand, rhOX40 Ligand, rhTRAIL and less than 1% cross-reactivity with rhAPRIL, rhLIGHT, rhTNF-alpha, rhVEGI, and rhTRANCE is observed.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
E. coli-derived recombinant human TWEAK Arg93-His249 Accession # Q4ACW9
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Recombinant Human TWEAK/TNFSF12 (Catalog # 1090-TW)
Immunocytochemistry
5-15 µg/mL
See below
Neutralization
Measured by its ability to neutralize TWEAK/TNFSF12-induced inhibition of proliferation in the HT‑29 human colon adenocarcinoma cell line. Yu, K. Y. et al. (1999) J. Biol. Chem. 274:13733; Harrop, J. A. et al. (1998) J. Biol. Chem. 273:27548The Neutralization Dose (ND50) is typically 2-8 µg/mL in the presence of 1 µg/mL Recombinant Human TWEAK/TNFSF12.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
General Protocols
are available in the Technical Information section on our website.
TWEAK/TNFSF12 Inhibition of Cell Proliferation and Neutralization by Human TWEAK/TNFSF12 Antibody.
Recombinant Human TWEAK/TNFSF12 (Catalog # 1090-TW) inhibits proliferation in the the HT‑29 human colon adenocarcinoma cell line in a dose-dependent manner (orange line). Activity elicited by Recombinant Human TWEAK/TNFSF12 (1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TWEAK/ TNFSF12 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1090). The ND50 is typically 2-8 µg/mL.
TWEAK/TNFSF12 in MDA-MB-231 Human Cell Line.
TWEAK/TNFSF12 was detected in immersion fixed MDA-MB-231 human breast cancer cell line using 10 µg/mL Goat Anti-Human TWEAK/TNFSF12 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1090) for 3 hours at room temperature. Cells were stained with the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.
Preparation and Storage
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: TWEAK/TNFSF12
TWEAK is a type II transmembrane protein belonging to the TNF superfamily (1). It contains a short cytoplasmic domain (amino acids (aa) 1-18), the transmembrane domain (aa 19-42) and an extracellular domain (aa 43-249). The extracellular domains of human and murine TWEAK share 89% aa sequence identity. A soluble form of TWEAK is generated from the membrane-associated molecules by proteolytic cleavage after Arg 93 suggesting that TWEAK may have long-range effects. TWEAK is expressed widely in many tissues and cells. At least two receptors that bind TWEAK have been identified (2-4). Death Receptor 3 (DR3), also known as TNFRSF12, Apo-3, LARD, WSL-1, or TRAMP, is a TNF receptor superfamily member that is expressed predominantly in tissues with high lymphocyte content (2). It has been suggested that induction of cell death by TWEAK-DR3 interaction involves the activation of NF-kappa B. In cells that lack DR3, alternate pathways of TWEAK-induced cell death mediated by receptors distinct from DR3 have been suggested (5, 6). TWEAK receptor (TWEAKR, alternatively known as FN14), is a novel TNF receptor superfamily member that also binds TWEAK (3, 4). It is a mitogen-inducible gene that is expressed in fibroblasts, hepetocellular carcinomas and endothelial cells. TWEAK-TWEAKR interaction has been shown to play a role in endothelial cell growth and migration. This effect of TWEAK is not mediated by an up-regulation of VEGF (7).
References:
Chicheportiche, Y. et al. (1997) J. Biol Chem. 272:32401.
Marsters, S. et al. (1998) Current Biol. 8:525.
Wiley, S.R. et al. (2001) Immunity, 15:837.
Feng, S-L.Y. et al. (2000) Am J. Path. 156:1253.
Nakayama, M. et al. (2002) J. Immunol. 168:734.
Schneider, P. et al. (1999) Eur. J. Immunol., 29:1785.
Lynch, C. et al. (1998) J. Biol. Chem. 274:8455.
Long Name:
TNF-like and Weak Inducer of Apoptosis
Entrez Gene IDs:
8742 (Human); 21944 (Mouse); 360548 (Rat)
Alternate Names:
APO3 ligand; APO3LMGC20669; DR3LGTWEAKAPO3/DR3 ligand; MGC129581; TNF-related weak inducer of apoptosis; TNFSF12; tumor necrosis factor (ligand) superfamily, member 12; tumor necrosis factor ligand superfamily member 12; TWEAK
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.